Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be patients between the ages of 18 years and 65 years who have been diagnosed with Pompe Disease, confirmed by mutational analysis and/or GAA enzyme activity assay.~* Receiving rhGAA ERT~* Willing to travel to the study site for study assessments~* Willingness of local medical treatment provider to continue treating study participant with addition of Zavesca® to treatment plan.~* Willingness of study participant to modify dietary intake on day of infusion \*All Subjects will continue enzyme replacement therapy as standard of care, as prescribed by local medical treatment provider during the course of the Study.~Exclusion Criteria:~* Subject is unable to meet the study requirements~* Subject's medical condition contraindicates participation or Study Investigators feel that participation is otherwise not in the Subject's best interest~* Subject does not receive ERT treatment~* Participation in other interventional studies at the time of enrollment that may interfere with this study (at the investigator's discretion)~* Unable to travel to the University of Florida for study visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Zavesca® 100 mg (Type: ACTIVE_COMPARATOR): 3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.
- Zavesca® 300 mg (Type: ACTIVE_COMPARATOR): 3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).